Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer
NCT01171755
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
19
Enrollment
OTHER
Sponsor class
Stopped
The objective response rate by more than two people are confirmed.
Conditions
Biliary Tract Cancer
Interventions
DRUG:
Gemcitabine TS-1
Sponsor
Samsung Medical Center